Pitt Street Research Briefing on Prescient Therapeutics
Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.
Stuart discussed the key highlights, below:
- How the potential of PTX-100 is “not just trouncing existing standards of care, but working in patients where previous treatments have failed.”
- How PTX-100, possibly “with a price of US$450,000 (using Acrotech Biopharma’s Folotyn as a guide)…could make US$2.5bn in sales”.
- The several catalysts beyond the current trial – including PTX-100’s potential to fight against 22% of all cancers.
Recorded on 11th July 2025 at 2pm (AEST).
Featured Speaker
Stuart Roberts
Co-Founder and Senior AnalystPitt Street Research
Stuart covered healthcare and biotechnology for the stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015 where he developed a reputation for detailed analysis on previously uncovered Life Science companies. After 15 months working for two ASX-listed drug development companies in 2015 and early 2016 he returned to equities research, co-founding Pitt Street Research.
Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Pitt Street Research Pty Ltd has been engaged and paid by the Prescient Therapeutics Limited for ongoing research coverage.
Any advice contained within this presentation is general advice and does not consider your personal circumstances, you should consider whether it is appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.
Past performance is not a reliable indicator of future performance.
This update is being hosted by Reach Markets Pty Ltd (CAR of AFSL 333297) and Reach does not assume responsibility for the accuracy or completeness of any information provided, and any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.
Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.
